Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

21.5%

35 terminated/withdrawn out of 163 trials

Success Rate

77.3%

-9.2% vs industry average

Late-Stage Pipeline

37%

60 trials in Phase 3/4

Results Transparency

52%

62 of 119 completed trials have results

Key Signals

1 recruiting62 with results30 terminated5 withdrawn

Enrollment Performance

Analytics

Phase 2

55(36.2%)

Phase 3

35(23.0%)

Phase 1

26(17.1%)

Phase 4

25(16.4%)

N/A

10(6.6%)

Early Phase 1

1(0.7%)

152Total

Phase 2(55)

Phase 3(35)

Phase 1(26)

Phase 4(25)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (163)

Showing 20 of 163 trials

NCT00539591Phase 2Active Not Recruiting

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Role: collaborator

NCT00629343Phase 1Completed

Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide

Role: collaborator

NCT00652301Phase 3Completed

A Research Study to Evaluate MK0653 (Ezetimibe) and Simvastatin, Given Together and Alone, on Intestinal Absorption of Cholesterol (0653-050)(COMPLETED)

Role: collaborator

NCT00653276Phase 1Completed

MD Ezetimibe Cyclosporine Interaction (0653-057)

Role: collaborator

NCT00423579Phase 4Completed

The Effects of Ezetimibe/Simvastatin 10/20 mg Versus Simvastatin 40 mg in High Cholesterol and Coronary Heart Disease Study (P04039AM2)(COMPLETED)

Role: collaborator

NCT00588523Phase 2Completed

Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma

Role: collaborator

NCT00574730Not ApplicableCompleted

CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma

Role: collaborator

NCT03324633Completed

Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV

Role: collaborator

NCT00591370Phase 2Completed

Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma

Role: collaborator

NCT00258960Phase 2Completed

Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer

Role: collaborator

NCT00128778Phase 4Completed

Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients

Role: collaborator

NCT00916747Phase 2Unknown

Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria

Role: collaborator

NCT01458730Phase 2Completed

Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma

Role: collaborator

NCT00413972Phase 3Completed

Effects of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia (Study P04420)

Role: collaborator

NCT00423488Phase 3Completed

Ezetimibe and Simvastatin in Primary Hypercholesterolemia, Diabetes Mellitus Type 2, and Coronary Heart Disease (COMPLETED)

Role: collaborator

NCT00000989Not ApplicableCompleted

The Safety and Effectiveness of Ganciclovir Used Alone or in Combination With Granulocyte-Macrophage Colony Stimulating Factor in the Treatment of Cytomegalovirus (CMV) of the Eye in Patients With AIDS

Role: collaborator

NCT00000658Phase 3Completed

A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma

Role: collaborator

NCT00001114Phase 2Completed

The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma

Role: collaborator

NCT01277419Recruiting

German Spondyloarthritis Inception Cohort

Role: collaborator

NCT00525031Phase 2Completed

Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients

Role: collaborator